Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system

Case Reports in Medicine

Volumn 2011, Issue , 2011, Pages

  Kasi, Pashtoon Murtaza ^a   Mounzer, Rawad ^a   Gleeson, George H ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; FLUOXETINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR EFFECT; CASE REPORT; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; DRUG METABOLISM; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART PALPITATION; HEART RATE; HUMAN; MALE; MEDICAL HISTORY; MYDRIASIS; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; RAYNAUD PHENOMENON; SIDE EFFECT; SINUS TACHYCARDIA; SUDDEN DEATH; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TIC;

EID: 84868005176     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2011/952584     Document Type: Article

References (11)

1. Hazell P., Becker K., Nikkanen E. A., Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder Attention Deficit and Hyperactivity Disorders 2009 1 2 201 210
2. Wehmeier P. M., Schacht A., Escobar R., Savill N., Harpin V., Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: meta-analysis of five atomoxetine trials Child and Adolescent Psychiatry and Mental Health 2010 4, article no. 30
3. Bastiaens L., Effectiveness and tolerability of atomoxetine in a real-world ADHD population: nonrandomized comparison with stimulants Psychiatry (Edgmont) 2007 4 12 44 48
4. Hammerness P., McCarthy K., Mancuso E., Gendron C., Geller D., Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review Neuropsychiatric Disease and Treatment 2009 5 1 215 226
5. Scherer D., Hassel D., Bloehs R., Zitron E., Von Lwenstern K., Seyler C., Thomas D., Konrad F., Brgers H. F., Seemann G., Rottbauer W., Katus H. A., Karle C. A., Scholz E. P., Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents British Journal of Pharmacology 2009 156 2 226 236
6. Ledbetter M., Atomoxetine: a novel treatment for child and adult ADHD Neuropsychiatric Disease and Treatment 2006 2 4 455 466 (Pubitemid 46321875)
7. Prescribing Information on Strattera. Eli Lilly and Company, pp. 117, http://pi.lilly.com/us/strattera-pi.pdf
8. Wernicke J. F., Faries D., Girod D., Brown J. W., Gao H., Kelsey D., Quintana H., Lipetz R., Michelson D., Heiligenstein J., Cardiovascular effects of atomoxetine in children, adolescents, and adults Drug Safety 2003 26 10 729 740 (Pubitemid 36976134)
9. Barton J., Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder Archives of Disease in Childhood 2005 90 1 i26 i29 (Pubitemid 40187999)
10. Sauer J. M., Ring B. J., Witcher J. W., Clinical pharmacokinetics of atomoxetine Clinical Pharmacokinetics 2005 44 6 571 590 (Pubitemid 40994086)
11. Rajesh A. S., Bates G., Wright J. G. C., Atomoxetine-induced electrocardiogram changes Archives of Disease in Childhood 2006 91 12 1023 1024 (Pubitemid 44863145)